Literature DB >> 1378371

Pharmacological differences of serotonin reuptake inhibitors and possible clinical relevance.

B E Leonard1.   

Abstract

Depression is a heterogeneous disease state characterised by complex alterations in several CNS neurotransmitter and receptor systems. All antidepressants are thought to act by causing postsynaptic adaptive changes (e.g. in transducers or second messengers) within these systems. Thus, the mechanism of action of selective serotonin reuptake inhibitors (SSRIs) cannot simply be explained in terms of inhibition of serotonin (5-hydroxytryptamine) [5-HT] reuptake. Fluvoxamine, sertraline and fluoxetine downregulate central beta-adrenoceptors, and all SSRIs are believed to normalise central 5-HT1A- and 5-HT2-receptor density and function in patients with depression. SSRIs are as effective as tricyclic antidepressants in the treatment of depression, but have distinct tolerability advantages--they are not associated with anticholinergic adverse effects, cardiotoxicity, sedation or weight gain. However, gastrointestinal reactions (e.g. nausea, diarrhoea/loose stools, constipation) are relatively common during SSRI therapy. Additionally, in contrast to tricyclic antidepressants, SSRI dosage adjustments appear to be unnecessary in elderly depressed patients. Fluvoxamine has a much shorter elimination half-life than fluoxetine and its active metabolite, norfluoxetine, and therefore a reduced potential for drug interactions. Only small amounts of fluvoxamine and fluoxetine, but large quantities of paroxetine, are secreted in breast milk. Furthermore, genetic polymorphism has not been documented for fluvoxamine metabolism, whereas slow and fast metabolisers of paroxetine, and fast metabolisers of fluoxetine have been identified. SSRIs have a better tolerability profile than tricyclic antidepressants, as indicated by lower mean rank scores for behavioural toxicity. Moreover, SSRIs are associated with a much lower incidence of fatal toxicity than tricyclics, and appear to be relatively safe in overdosage.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1378371     DOI: 10.2165/00003495-199200432-00003

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  19 in total

Review 1.  Pharmacological and biochemical aspects of therapy-resistant depression.

Authors:  B E Leonard
Journal:  Int Clin Psychopharmacol       Date:  1991-07       Impact factor: 1.659

Review 2.  Antidepressants: current concepts of mode of action.

Authors:  P J Cowen
Journal:  Int Clin Psychopharmacol       Date:  1990-07       Impact factor: 1.659

Review 3.  Serotonin receptor and reuptake sites: pharmacologic significance.

Authors:  J Gonzalez-Heydrich; S J Peroutka
Journal:  J Clin Psychiatry       Date:  1990-04       Impact factor: 4.384

Review 4.  Clinical pharmacology and pharmacokinetics of fluoxetine: a review.

Authors:  R F Bergstrom; L Lemberger; N A Farid; R L Wolen
Journal:  Br J Psychiatry Suppl       Date:  1988-09

5.  Excretion of fluoxetine in human breast milk.

Authors:  K E Isenberg
Journal:  J Clin Psychiatry       Date:  1990-04       Impact factor: 4.384

Review 6.  A review of the metabolism and pharmacokinetics of paroxetine in man.

Authors:  C M Kaye; R E Haddock; P F Langley; G Mellows; T C Tasker; B D Zussman; W H Greb
Journal:  Acta Psychiatr Scand Suppl       Date:  1989

Review 7.  Sertraline: a new antidepressant.

Authors:  D P Doogan; V Caillard
Journal:  J Clin Psychiatry       Date:  1988-08       Impact factor: 4.384

Review 8.  The antidepressant effects of 5-HT uptake inhibitors.

Authors:  A Aberg-Wistedt
Journal:  Br J Psychiatry Suppl       Date:  1989-12

9.  Decreased beta-adrenergic receptors in rat brain after chronic administration of the selective serotonin uptake inhibitor fluoxetine.

Authors:  W F Byerley; E J McConnell; R T McCabe; T M Dawson; B I Grosser; J K Wamsley
Journal:  Psychopharmacology (Berl)       Date:  1988       Impact factor: 4.530

Review 10.  Fluoxetine drug-drug interactions: I. Antidepressants and antipsychotics.

Authors:  D A Ciraulo; R I Shader
Journal:  J Clin Psychopharmacol       Date:  1990-02       Impact factor: 3.153

View more
  21 in total

1.  The Use of Alosetron to Treat SSRI-Induced Gastrointestinal Symptoms.

Authors:  Timothy R. Berigan; Karl N. Zeff
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2000-08

Review 2.  Tolerability of selective serotonin reuptake inhibitors: issues relevant to the elderly.

Authors:  Brian Draper; Karen Berman
Journal:  Drugs Aging       Date:  2008       Impact factor: 3.923

Review 3.  Risks and benefits of selective serotonin reuptake inhibitors in the treatment of depression.

Authors:  P Mourilhe; P E Stokes
Journal:  Drug Saf       Date:  1998-01       Impact factor: 5.606

Review 4.  Paroxetine. A pharmacoeconomic evaluation of its use in depression.

Authors:  M I Wilde; R Whittington
Journal:  Pharmacoeconomics       Date:  1995-07       Impact factor: 4.981

Review 5.  Treatment of uncontrolled crying after stroke.

Authors:  G Andersen
Journal:  Drugs Aging       Date:  1995-02       Impact factor: 3.923

6.  Deciding which selective serotonin reuptake inhibitor to prescribe.

Authors:  A J Cleare
Journal:  BMJ       Date:  1995-12-16

Review 7.  Drug therapy for geriatric depression.

Authors:  R Bressler; M D Katz
Journal:  Drugs Aging       Date:  1993 May-Jun       Impact factor: 3.923

Review 8.  Drug-induced cognitive impairment. Defining the problem and finding solutions.

Authors:  J D Bowen; E B Larson
Journal:  Drugs Aging       Date:  1993 Jul-Aug       Impact factor: 3.923

Review 9.  Sertraline: a review of its use in the management of major depressive disorder in elderly patients.

Authors:  Richard B R Muijsers; Greg L Plosker; Stuart Noble
Journal:  Drugs Aging       Date:  2002       Impact factor: 3.923

Review 10.  Fluvoxamine. An updated review of its pharmacology, and therapeutic use in depressive illness.

Authors:  M I Wilde; G L Plosker; P Benfield
Journal:  Drugs       Date:  1993-11       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.